Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Ventricular Tachycardia:A Registry Study

A legfontosabb adatok

Ki végzi
Beijing Anzhen Hospital
Hol
Beijing (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
1000 fő, tervezett
Kezdés
2025. okt. 14.
Várható befejezés
2029. dec. 1.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Standard Clinical Care
A regiszteradat frissítve
2026. július 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with structural heart disease and a fast abnormal heart rhythm from the lower heart chambers (ventricular tachycardia). It only observes their usual care.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Sustained ventricular tachycardia, or short episodes (nonsustained) that the doctor thinks need treatment. It must be confirmed by a heart recording or heart test. Structural heart disease must be diagnosed under current guidelines.
Korábbi kezelés
No heart surgery in the 60 days before joining.

A részvétel fő kizáró okai

  • Ventricular tachycardia from a reversible cause, such as acute lack of blood flow to the heart or salt imbalances in the blood
  • Ventricular tachycardia with no sign of structural heart disease
  • Severe infection, such as sepsis or septic shock
  • Severe bleeding or clotting problems, including platelet count <50 × 10⁹/L or disseminated intravascular coagulation
  • Taking part in another treatment study that may interfere with this registry

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults aged ≥18 years
  • Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study
  • Structural heart disease diagnosed according to current clinical guidelines
  • Willing and able to provide written informed consent
  • Willing to comply with the study follow-up schedule

Ki nem vehet részt

  • Cardiac surgery within 60 days before enrollment
  • Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances)
  • Idiopathic ventricular tachycardia without evidence of structural heart disease
  • Severe infectious diseases (e.g., septic shock or sepsis)
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation
  • Severe coagulation disorders, including platelet count <50 × 10⁹/L or disseminated intravascular coagulation
  • Participation in another interventional clinical study that may interfere with this registry

Helyszínek itt: Kína

  • Beijing Anzhen Hospital, Capital Medical UniversityBeijing, KínaContact: Deyong Long, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.

A vizsgálat csoportja

  • SHD-VT Cohort

    This cohort includes consecutive adult patients with structural heart disease and documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, enrolled in a prospective multicenter observational registry. All treatment decisions are made according to routine clinical practice without study intervention.

    Kezelés: Standard Clinical Care

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. július 29.